I used Epifix at the hospital today and asked the nurse if he had seen it before. He acknowledged seeing 60 or so cases this year on colon and prostate cases. The product is really starting to take off for surgical and I imagine the same across the country.
A recent 100 patient prospective clinical trial compared Epifix to Apligraf and standard wound care(SWC). After 12 weeks, Epifix resulted in 97% complete wound closure while Apligraf only 73% and SWC 51%. Another study of 97 patients compared Grafix to SWC and after 12 weeks 62% of Grafix patients achieved complete wound closure while only 21% of SWC achieved complete wound closure.
So, Epifix is obviously the best choice from clinical clinical results and ease of use/storage/costs. Results Epifix-97%, Apligraf-73%, Grafix-62% and SWC-21% to 51%. Apligraf is second best and Grafix is only slightly better than SWC. So, if someone really wants to use the frozen stuff, they should consider Apligraf or just SWC. This is likely why sales/use statistics show Epifix a market leader with Apligraf/Dermagraf second and Grafix a distant third. This is why Osiris hides the sales numbers for Grafix. Plus, their other products likely will never fully gain market acceptance and you can see why Osiris is going down the tubes.
Mimedx will be acquired likely late 2016 for at least double the current price and Osiris will continue to drop to about 7 per share, maybe lower. Those backing him will be unhappy.
Of product use. The new lines of business will swell revenues.
That is very bullish. He knows what a bargain this company is at these prices. I wish I could buy a ton like he just did. He knows revenues are going to ramp up, especially in the second half 2016.
Surgical apps for Mimedx ready for parabolic growth. Surgeon awareness and colleague use is the key..
Time to put another Ozark alias on ignore. Follow the revenue and earnings for Mimedx the next 24 months and you will see. No need for a minute to minute blow by blow analysis, but I guess that is the type person you are.
NICE is a United Kingdom organization, but We no nothing of their materials and methods etc. Skeptical and the market leader, Epifix research proven best of class not included. I noted in Grafix study there were 18 year olds in the study. Give me a break, the healing potential of an 18 year old is phenomenal. Amnion only, dying cell is no match for Epifix. The best thing you could do now for your clients is sell Osiris short and cover your short on Mimedex.
No one has talked much about the Physio product Mimedx is getting with Stability. That is a home run. Physio has BMP, VEGF and CaP with several forms for easy bone grafting, resistance and retentiun form. Infuse works great but can cause unpredictable swelling that is an issue with spine surgery. With the right marketing team Physio will be a category killer.
Gentlemen this is how Enron and World Comm appeared. Auditors, science officers, corporate attorneys, CFOs and CEOs leaving. Lawyers and the attorney general's office will soon blot out the sky over OSIR. Corporate malfeasance spells disaster. Hope for buyout, but there is reluctance to assume liability. You could still save something by selling now.
Cezass is a loser, Ozark who led Osiris investors astray. Mimedx is set up for big gains the next couple years. Patents in cancer, anti-fungal and microbial, heart and nerve regeneration will be enticing for companies seeking M&A. Several revenue generators will be playing out this year.
Revenue and earnings about to pass a threshold as Docs recognize healing capacity of amnion Chorian and Collafix unleashed. Several partnerships and buyout looming. Shorts are on the clock.
Not concerned about you or Mimedx. This message is to warn anyone mislead regarding this company. If they choose to stay invested, that is their prerogative. You might say you were mislead also. If you continue trying to mislead people, you are dispicable.
He said he used to use Apligraf and Dermageaf and take the patients to the hospital because of frozen and handling. Now he uses Epifix exclusively and used in office because it is so easy to use, store and efficacy. He is also using injectable Amniofix
Maybe if an elite auditor came on board and all finances were legit for an extended period, faith might be restored. Otherwise better off being acquired. Most investors should vacate or be prepared for more losses.
Investment firms like Blackrock do their homework. They see the research projects out there and how that translates to sales. They see strategic alliances present and future and see how that translates to sales. They see identified markets and realize Mimedex products will dominate those markets. Collafix and Physio next up. Look for more deals.